|
|
Volumn 34, Issue 5, 2002, Pages 1918-1919
|
|
Steroid-resistant acute rejection following SPK: Importance of maintaining therapeutic dosing in a triple-drug regimen
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
INTERLEUKIN 2 RECEPTOR ANTIBODY;
METHYLPREDNISOLONE;
STEROID;
TACROLIMUS;
CORTICOSTEROID;
DACLIZUMAB;
DRUG DERIVATIVE;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
MYCOPHENOLIC ACID;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
BIOAVAILABILITY;
CONFERENCE PAPER;
CONTROLLED STUDY;
GRAFT REJECTION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
MOLECULAR EVOLUTION;
PRIORITY JOURNAL;
REDUCTION;
ARTICLE;
DRUG ADMINISTRATION;
DRUG COMBINATION;
DRUG RESISTANCE;
GRAFT SURVIVAL;
IMMUNOLOGY;
KIDNEY TRANSPLANTATION;
MORTALITY;
PANCREAS TRANSPLANTATION;
PHYSIOLOGY;
RETROSPECTIVE STUDY;
SURVIVAL RATE;
TIME;
ADRENAL CORTEX HORMONES;
ANTIBODIES, MONOCLONAL;
DRUG ADMINISTRATION SCHEDULE;
DRUG RESISTANCE;
DRUG THERAPY, COMBINATION;
GRAFT SURVIVAL;
HUMAN;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
METHYLPREDNISOLONE;
MYCOPHENOLIC ACID;
PANCREAS TRANSPLANTATION;
RETROSPECTIVE STUDIES;
SURVIVAL RATE;
TACROLIMUS;
TIME FACTORS;
HUMANS;
|
|
EID: 0035993810
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(02)03122-6 Document Type: Conference Paper |
|
Times cited : (11)
|
|
References (6)
|
